{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 150 of 169', 'Panel 17 Classification of topical corticosteroids (continued)', 'Potency', 'Class', 'Topical corticosteroid', 'Formulation', 'Moderate', 'V', 'Hydrocortisone valerate', 'Cream, 0.2%', 'Triamcinolone acetonide', 'Lotion, 0.1%', 'Low', 'VI', 'Betamethasone valerate', 'Lotion, 0.05%', 'Desonide', 'Cream, 0.05%', 'Fluocinolone acetonide', 'Solution, 0.01%', 'VII', 'Dexamethasone sodium phosphate', 'Cream, 0.1%', 'Hydrocortisone acetate', 'Cream, 1%', 'Methylprednisolone acetate', 'Cream, 0.25%', 'Source: WHO model prescribing information: drugs used in skin diseases (41).', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 151 of 169', 'Appendix 10: Protocol amendment history', 'The Protocol amendment summary of changes table for the current amendment is located', 'directly before the table of contents.', 'Amendment 2 (12-Dec-2017)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a)', 'of Directive 2001/20/EC of the European Parliament and the Council of the European Union.', 'Overall rationale for the amendment', 'The reason for the amendment is due to a request for changes from the Health Authorities in', 'the US after their review of the protocol.', 'Note: The table below describes the changes in each section. Changes have either been', 'summarised (written with plain text only) or marked as tracked changes (text added to the', 'protocol is written in bold and deleted text has a-line through it).', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 152 of 169', 'Section number', 'Description of change', 'Brief rationale', 'and name', 'Section 6.1', 'EASI90 has been added as an additional', 'Added to further', 'Trial objectives and', 'secondary endpoint.', 'substantiate the clinical', 'endpoints: Initial', 'relevance of the treatment', 'treatment period of', 'effect on the change from', 'Weeks 0 to 16', 'baseline to Week 16 in', 'EASI score.', 'Section 6.1', 'The following other objective has been added:', 'Added to allow for an', 'Trial objectives and', 'To evaluate the efficacy over time of', 'evaluation of the efficacy', 'endpoints: Initial', 'tralokinumab on severity and extent of AD,', 'of tralokinumab over time', 'treatment period of', 'itch, and health-related quality of life', 'on severity and extent of', 'Weeks 0 to 16', 'compared with placebo.', 'AD, itch, and', 'health-related quality of', 'life compared with', 'placebo.', 'The following endpoints have been added as', 'Added to allow for an', 'other endpoints:', 'evaluation of the efficacy', 'IGA 0/1 at each scheduled assessment', 'of tralokinumab over time', 'until Week 14.', 'on severity and extent of', 'AD, itch, and', 'EASI75 at each scheduled assessment', 'until Week 14.', 'health-related quality of', 'life compared with', 'Change in SCORAD from baseline to', 'placebo.', 'each scheduled assessment until Week 14.', 'Change from baseline to each week', 'through Week 1 to 15 in Worst Daily', 'Pruritus NRS (weekly average).', 'Reduction of Worst Daily Pruritus NRS', '(weekly average) of at least 4 from', 'baseline to each week through Week 1 to', '15.', 'Change in DLQI score from baseline to', 'each scheduled assessment until Week 14.', 'The following other endpoints have been', 'Removed because these', 'removed:', '2 endpoints are covered by', 'Reduction of Worst Daily Pruritus NRS', 'the new endpoints above', '(weekly average) of at least 4 from', '(change from baseline to', 'baseline to Week 2', 'each week; reduction from', 'Change from baseline to Week 2 in Worst', 'baseline to each week).', 'Daily Pruritus NRS (weekly average).', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}